Saturday, December 12th 2020
SGT – 3 pm | CET – 8 am | UTC – 7 am | AET – 6 pm
Enhanced dose escalation – adding a brachytherapy boost to external beam radiation therapy – is associated with superior PSA-RFS (Prostate Specific Antigen – Relapse Free Survival) outcomes in intermediate risk prostate cancer patients compared with high-dose IMRT alone*.
Join us for a webinar with our clinical expert, Prof. Razvan Galalae, to hear his experiences in HDR brachytherapy for prostate cancer.
Prof. Razvan Galalae, MD, PhD
Associate Professor for Radiation Oncology (Venia Legendi – Christian-Albrechts-Univ. Kiel, Germany) & Clinical Director Interventional Particle Therapy